-

Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that two abstracts featuring data from the Company’s prostate specific membrane antigen artificial intelligence (PSMA AI) tool will be presented at the upcoming European Association of Nuclear Medicine (EAMN) Virtual Congress, which will be held from October 22-30, 2020. Details on the presentations are included below.

Oral Presentation
Title: Deep Learning-Enabled Comprehensive Detection and Quantification of 18FDCFPyL (PyL-PSMA) PET/CT
Presenter: Johan Brynolfsson; Data Scientist; EXINI Diagnostics AB, Lund, SWEDEN
Abstract ID: OP-548
Session Title: 1006: Cutting Edge Science Track - TROP Session: AI -Radiomics and Modelling
Date and Time: Saturday, October 24, 2020, 10:40 - 12:10 CEST on an “on demand” basis

e-Poster Presentation
Title: Deep-learning based urinary bladder segmentation using 18FDCFPyL (PyL-PSMA) PET/CT images
Presenter: Johan Brynolfsson; Data Scientist; EXINI Diagnostics AB, Lund, SWEDEN
Abstract ID: EPS-145
Session Title: 1411: e-Poster Presentation Session 9: Physics -Software and Image Processing
Date and Time: Friday, October 30, 2020, 09:00 - 10:30 CEST on an “on demand” basis

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Puerto Rico, Canada and Sweden. For more information, visit www.lantheus.com.

Contacts

Investors:
Mark Kinarney
Senior Director, Investor Relations
978-671-8842

Media:
Melissa Downs
Director, Corporate Communications
646-975-2533

Industry:

Lantheus Holdings, Inc.

NASDAQ:LNTH
Release Versions
English

Contacts

Investors:
Mark Kinarney
Senior Director, Investor Relations
978-671-8842

Media:
Melissa Downs
Director, Corporate Communications
646-975-2533

More News From Lantheus Holdings, Inc.

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation). Clinicians will have the option to utilize aPROMISE with PYLARIFY® (piflufolastat F 18) to increase the efficiency and reproducibility of their PSMA PET/CT assessm...

Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today reported financial results for its second quarter ended June 30, 2021. The Company’s worldwide revenue for the second quarter of 2021 totaled $101.1 million, compared with $66.0 million for the second...

Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 28, 2021, to discuss its financial and operating results for the second quarter of 2021. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 6149638. A live webcast will also be available in the Invest...
Back to Newsroom